We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Spinnovation Biologics Predicts Biomanufacturing Success
Product News

Spinnovation Biologics Predicts Biomanufacturing Success

Spinnovation Biologics Predicts Biomanufacturing Success
Product News

Spinnovation Biologics Predicts Biomanufacturing Success

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Spinnovation Biologics Predicts Biomanufacturing Success"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

With expertise and know-how in high-end analysis for biologics, Spinnovation Biologics has announced the launch of a solution - Spedia-Predict™ - for Bioprocess performance troubleshooting and performance prediction of bioproduction, at the annual Bioprocess International European meeting.

Spedia-Predict™ monitors and validates process-critical parameters as a company looks to manage the culture media consistency used in their production environment.

Good Manufacturing Practice (GMP) and FDA Quality by Design (QbD) approaches demand close control, but traditional analytical methodology can be costly, time consuming and require sample preparation ahead of measurement. They also lack the ability to characterize chemically complex media.

As a result, many companies monitor only a handful of components, failing to get the complete picture and missing information on how it will perform in scale-up.

Spedia-Predict™ rapidly profiles most constituents in a medium; it delivers quantitative data and can be applied equally to chemically fully defined or complex media.

Spedia-Predict™ allows identification of markers that can correlate with performance of a specific bioprocess, and monitor batch to batch consistency, for example.

As a result, it helps to prevent failure and performance variability in large-scale commercial production, by enabling efficient and cost-effective processes.

Dr Frederic Girard, CEO, said, “Using Spedia-Predict™ we help our clients to understand and monitor the factors that are most influential to their cell culture performance. This is a huge advantage. Importantly, we provide information early in production planning - effectively establishing a QC standard - which can then be used in routine manufacturing to reduce the risk of process failure, and increase the consistency in production performance. Risk factors are reduced and replaced with consistent, reproducible results.”

Spinnovation’s core expertise in Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) to study molecules and materials is increasingly being applied in the biopharma production environment.

The introduction of Spedia-Predict™ demonstrates the company’s continuous efforts to develop and implement new analytical methods to meet most demanding industry requirements.